{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Azenosertib",
    "query": {
      "intervention": "Azenosertib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Azenosertib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T05:42:30.253Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04516447",
      "title": "A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 172,
      "start_date": "2020-10-26",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 8,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04516447"
    },
    {
      "nct_id": "NCT06015659",
      "title": "ZN-c3 + Gemcitabine in Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Pancreatic Adenocarcinoma",
        "Pancreatic Cancer",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Zentalis",
          "type": "DRUG"
        },
        {
          "name": "Gemzar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brandon Huffman, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-11-16",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06015659"
    },
    {
      "nct_id": "NCT06369155",
      "title": "Azenosertib in Uterine Serous Carcinoma: Biomarker Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Serous Carcinoma",
        "Uterine Carcinoma",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joyce Liu, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2025-03-05",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06369155"
    },
    {
      "nct_id": "NCT04005690",
      "title": "Targeted Pathway Inhibition in Patients With Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Ductal Adenocarcinoma",
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Unresectable Pancreatic Ductal Adenocarcinoma",
        "Borderline Resectable Pancreatic Ductal Adenocarcinoma",
        "Resectable Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Onvansertib",
          "type": "DRUG"
        },
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Saruparib",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2019-08-01",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04005690"
    },
    {
      "nct_id": "NCT06364410",
      "title": "Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Gastric Carcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Gastric Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Unresectable Gastric Carcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-02-03",
      "completion_date": "2027-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06364410"
    },
    {
      "nct_id": "NCT06351332",
      "title": "ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Female",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Malignant Tumor Breast Triple",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Filipa Lynce, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2024-05-01",
      "completion_date": "2026-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06351332"
    },
    {
      "nct_id": "NCT04158336",
      "title": "A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2019-11-01",
      "completion_date": "2025-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Newport Beach, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04158336"
    },
    {
      "nct_id": "NCT04833582",
      "title": "A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-08-01",
      "completion_date": "2024-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Oakland, California • Santa Monica, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04833582"
    },
    {
      "nct_id": "NCT05198804",
      "title": "A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Platinum-resistant Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 117,
      "start_date": "2022-01-27",
      "completion_date": "2026-01-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Miami Beach, Florida + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05198804"
    },
    {
      "nct_id": "NCT07546500",
      "title": "A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Investigator's choice of Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Azenosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 420,
      "start_date": "2026-04-17",
      "completion_date": "2030-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-02T05:42:30.253Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Antioch, California • Beverly Hills, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07546500"
    }
  ]
}